ZoneOne Pharma
Nanoliposome-encapsulated desferrioxamine (LDFO) formulation for iron chelation therapy
- Sector
- Biotech
- Total capital
- $4M
- Federal grants
- $3.8M
- 6 awards · 2015–2016
- Rank in peer group#98 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $216K
- 1 award · Health and Human S
- Rank in Biotech#289 of 4373
- Granted patents
- 4
- 23 pending · first 2017
- Rank in peer group#35 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Non-irritating Sustained Release Cysteamine Eye Drops to Treat Cystinosis$238K
- Federal grantHealth and Human S · Phase II · Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$957K
- Federal grantHealth and Human S · Phase II · Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$1.5M
- Federal grantHealth and Human S · Phase I · Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells$299K
- Federal grantHealth and Human S · Phase I · Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells$299K
- Federal grantHealth and Human S · Phase II · Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$534K
- Federal contractHealth and Human S · Igf::ot::igf Other Functions - R&d Biomedical (basic Research)$216K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#98 · top 30%
- Granted patents#35 · top 11%
- Linked publications#4 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 27- GrantedRemote Loading Of Sparingly Water-soluble Drugs Into LiposomesUSPTOUS 10,722,467
- GrantedRemote Loading Of Sparingly Water-soluble Drugs Into LiposomesUSPTOUS 10,507,182
- PendingRemote Loading Of Sparingly Water-soluble Drugs Into Lipid VesiclesUSPTOApplication 15972012
Show all 27 patent records
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesJul 28, 2020 · US 10,722,467Granted
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesDec 17, 2019 · US 10,507,182Granted
- Remote Loading Of Sparingly Water-soluble Drugs Into Lipid VesiclesApr 11, 2019 · Application 15972012Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into Lipid VesiclesJun 26, 2018 · US 10,004,759Granted
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesAug 22, 2017 · US 9,737,485Granted
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesJul 20, 2017 · Application 15429113Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemMay 11, 2017 · Application 15413362Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemSep 18, 2014 · Application 14214345Pending
- Transformation Of Drug Cyclodextrin Complex Compositions Into Compositions Of Mixtures Of Lipid Vesicle Encapsulated Drug And Cyclodextrin Drug ComplexesAug 7, 2014 · Application 14171728Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesAug 7, 2014 · Application 14171619Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesAug 7, 2014 · Application 14171654Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesApplication PCTUS2014014480Pending
- Transformation Of Drug Cyclodextrin Complex Compositions Into Compositions Of Mixtures Of Lipid Vesicle Encapsulated Drug And Cyclodextrin Drug ComplexesApplication PCTUS2014014510Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemApplication 61785503Pending
- Transformation Of Drug Cyclodextrin Complex Compositions Into Compositions Of Mixtures Of Lipid Vesicle Encapsulated Drug And Cyclodextrin Drug ComplexesApplication 61760410Pending
- Transformation Of Drug Cyclodextrin Complex Compositions Into Compositions Of Mixtures Of Lipid Vesicle Encapsulated Drug And Cyclodextrin Drug ComplexesApplication 61759923Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into LiposomesApplication 61759914Pending
- Synthesis Of New Methylumbelliferone Prodrugs And Their Incorporation Into Lipid-based Drug Delivery FormulationsApplication PCTUS2017040282Pending
- Synthesis Of New Methylumbelliferone Prodrugs And Their Incorporation Into Lipid-based Drug Delivery FormulationsApplication 62516578Pending
- Synthesis Of New Methylumbelliferone Prodrugs And Their Incorporation Into Lipid-based Drug Delivery FormulationsApplication 62357680Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemApplication PCTUS2015044878Pending
- Pharmaceutical Formulations Of And Methods To Prepare Chelating Agents For Efficient Metal Removal Treatment SystemsApplication PCTUS2015044781Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into Lipid VesiclesApplication PCTUS2015043594Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemApplication 62037044Pending
- Pharmaceutical Formulations Of And Methods To Prepare Chelating Agents For Efficient Metal Removal Treatment SystemsApplication 62037034Pending
- Remote Loading Of Sparingly Water-soluble Drugs Into Lipid VesiclesApplication 62033073Pending
- Pharmaceutical Formulations Of Chelating Agents As A Metal Removal Treatment SystemApplication PCTUS2014029530Pending
Recent research by its founders
- Liposome Formulation of Carfilzomib with Improved Activity As a Monotherapy and in Combination with Vinblastine20221 cites
- A hitchhiker’s guide to mucosal and systemic immunity20220 cites
- Manipulating the Intracellular Trafficking of Nucleic Acids20204 cites
Related companies, and why
- LaCell LLCSimilar federal contract value in Biotech · $235K in contracts
- Global Blood TherapeuticsSimilar federal contract value in Biotech · $219K in contracts
- THERMOGENESIS CORP.Similar federal contract value in Biotech · $218K in contracts
- Edesa Biotech, Inc.Similar federal contract value in Biotech · $214K in contracts
- THE TINY CARGO COMPANYSimilar federal contract value in Biotech · $210K in contracts
- Ursa AnalyticsSimilar federal contract value in Biotech · $205K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .